Pfizer’s Neurontin Marketing Hurt Payors, 1st Circuit Hears

Blue Cross Blue Shield of Louisiana and other third-party payors struck back at Pfizer in their bid to return their case to multidistrict litigation over alleged off-label marketing of epilepsy drug Neurontin (gabapentin), telling the 1st Circuit they had enough evidence to prove their claims of direct injury.
Law360